Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (PCV13)

Inclusion Criteria:

• Patients with confirmed multiple myeloma
• Eligible for treatment with high dose melphalan based regimen and autologous peripheral stem cell transplant

Exclusion Criteria:

• Pregnant or lactating woman, as evaluated by serum testing within 24 hours of administration of the first vaccine
• HIV infection confirmed by nucleic acid testing (NAT), as evaluated during pre transplant testing
• Common variable immunodeficiency or other inherited systemic immunodeficiency syndrome
• Active central nervous system (CNS) malignancy
• Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy.
• History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal conjugate vaccine 7 (PCV7), PCV13, or any diphtheria-toxoid containing vaccine.
• Inclusion on a separate trial in which patients may be randomized or otherwise started on maintenance chemotherapies within the first 3 months of autologous transplantation
• Patients with significant psychiatric illness likely to affect compliance, as determined by the treating physician
• Active or uncontrolled infection
• Diffusing lung capacity oxygenation (DLCO) <50 %
• Left ventricular ejection fraction (LVEF) <40%
• Bilirubin >2